Immunomodulation due to coexposure to styrene and dioctyl phthalate in mice

Pathomorphological and immunological alterations caused by a mixture of styrene and dioctyl phthalate were studied in albino mice following oral administration of 0.02, 0.03, 0.05 x LD50 of the mixture. The chemicals were mixed together proportionate to their respective LD50 values and fed in ground nut oil, 5 d/wk for 4 weeks. Histological examination of spleen revealed considerable depletion of cellular population of lymphoid follicles which corresponded to the dose dependent decrease in splenic mononuclear cell population count. The thymic lobules revealed slight atrophy but accompanied by a significant increase in thymocyte population. Correspondingly few significant histological changes were observed in mesenteric and peripheral lymph nodes. The treatment caused impairment of primary humoral immune response to SRBC (IgM) but there was a significant increase in response of splenocytes to B-cell mitogen LPS. There was a suppression of cutaneous delayed type hypersensitivity and increase in splenic lymphocyte response to T-cell mitogen PHA. Simultaneously, indirect immunity represented by decreased phagocytosis and enhanced metabolic function of reducing NBT by peritoneal exudate cells was observed. The in vitro exposure of vero cells to the mixture caused dose dependent protective effect. The results of present study indicate that subchronic exposure to low doses of mixture of styrene and dioctyl phthalate under certain conditions may modulate some of the immune functions as compared to exposure to either chemicals alone.

Species-specific pharmacokinetics of styrene in rat and mouse

The pharmacokinetics of styrene were investigated in male Sprague-Dawley rats and male B6C3F1 mice using the closed chamber technique. Animals were exposed to styrene vapors of initial concentrations ranging from 550 to 5000 ppm, or received intraperitoneal (i.p.) doses of styrene from 20 to 340 mg/kg or oral (p.o.) doses of styrene in olive oil from 100 to 350 mg/kg. Concentration-time courses of styrene in the chamber atmosphere were monitored and analyzed by a pharmacokinetic two-compartment model. In both species, the rate of metabolism of inhaled styrene was concentration dependent. At steady state it increased linearly with exposure concentration up to about 300 ppm; more than 95% of inhaled styrene was metabolized and only small amounts were exhaled unchanged. At these low concentrations transport to the metabolizing enzymes and not their metabolic capacity was the rate limiting step for metabolism. Pharmacokinetic behaviour of styrene was strongly influenced by physiological parameters such as blood flow and especially the alveolar ventilation rate. At exposure concentrations of styrene above 300 ppm the rate of metabolism at steady state was progressively limited by biochemical parameters of the metabolizing enzymes. Saturation of metabolism (Vmax) was reached at atmospheric concentrations of about 700 ppm in rats and 800 ppm in mice, Vmax being 224 mumol/(h.kg) and 625 mumol/(h.kg), respectively. The atmospheric concentrations at Vmax/2 were 190 ppm in rats and 270 ppm in mice. Styrene accumulates preferentially in the fatty tissue as can be deduced from its partition coefficients in olive oil:air and water:air which have been determined in vitro at 37 degrees C to be 5600 and 15. In rats and mice exposed to styrene vapors below 300 ppm, there was little accumulation since the uptake was rate limiting. The bioaccumulation factor body:air at steady state (K'st*) was rather low in comparison to the thermodynamic partition coefficient body:air (Keq) which was determined to be 420. K'st* increased from 2.7 at 10 ppm to 13 at 310 ppm in the rat and from 5.9 at 20 ppm to 13 at 310 ppm in the mouse. Above 300 ppm, K'st* increased considerably with increasing concentration since metabolism became saturated in both species. At levels above 2000 ppm K'st* reached its maximum of 420 being equivalent to Keq. Pretreatment with diethyldithiocarbamate, administered intraperitoneally (200 mg/kg in rats, 400 mg/kg in mice) 15 min prior to exposure of styrene vapours, resulted in effective inhibition of styrene metabolism, indicating that most of the styrene is metabolized by cytochrome P450-dependent monooxygenases.(ABSTRACT TRUNCATED AT 400 WORDS)

Neurochemical effects in rats following gestational exposure to styrene

Styrene was evaluated for the reproductive effects of pregnant rats and the neurochemical effects in the offspring of rats exposed during gestation. Pregnant Wistar rats were exposed to 0, 50, or 300 ppm styrene for 6 h/day during days 7 to 21 of gestation. No significant differences in the number of offspring delivered were observed between the exposed and control groups. Body weights at 1 day of age of the offspring whose mothers were exposed to styrene were significantly lower than those of the control group. Although, there were neither statistically significant differences of protein contents nor brain weights among styrene-exposed and their control offsprings of rats, analyses of neurotransmitter studies showed dose-dependent decreases of neuroamines, especially 5-HT (serotonin) and its metabolite 5HIAA (5-hydroxyindoleacetic acid) in the newborn offspring of styrene-exposed rats. The results suggest that gestational exposure to styrene at these concentrations does not produce apparent reproductive toxicity but affects the body weight of pups and causes lowering of the neurotransmitter levels in the brain.

Cytogenetic studies of mice exposed to styrene by inhalation

The data for the in vivo genotoxicity of styrene (STY) are equivocal. To evaluate the clastogenicity and sister-chromatid exchange (SCE)-inducing potential of STY in vivo under carefully controlled conditions, B6C3F1 female mice were exposed by inhalation for 6 h/day for 14 consecutive days to either 0, 125, 250 or 500 ppm STY. One day after the final exposure, peripheral blood, spleen, and lungs were removed and cells were cultured for the analysis of micronucleus (MN) induction using the cytochalasin B-block method, chromosome breakage, and SCE induction. Peripheral blood smears were also made for scoring MN in erythrocytes. There was a significant concentration-related elevation of SCE frequency in lymphocytes from the spleen and the peripheral blood as well as in cells from the lung. However, no statistically significant concentration-related increases were found in the frequency of chromosome aberrations in the cultured splenocytes or lung cells, and no significant increases in MN frequencies were observed in binucleated splenocytes or normochromatic erythrocytes in peripheral blood smears.

Effect of styrene on testicular enzymes of growing rat

Effect of styrene (100 or 200 mg/kg body wt/day) for 60 days was observed on testicular enzymes of postnatally maturing rats. A significant decrease in epididymal spermatozoa count was observed only at 200 mg/kg body weight dose. Activities of testicular sorbitol dehydrogenase and acid phosphatase decreased while activities of lactate dehydrogenase, beta-glucuronidase, glucose-6-phosphate dehydrogenase, and gamma-glutamyl transpeptidase significantly increased only in animals exposed to styrene at a dose of 200 mg/kg body weight. The results suggest that exposure to high dose of styrene during developmental period alters the activities of enzymes associated with specific cell type of testis.

[The effect of elevated amounts of ascorbic acid on the status of the vitamin and lung disorders in guinea pigs inhaling styrene]

An inhalation intoxication with styrene is performed on guinea pigs--600 mg.m-3, 5 hrs daily, 5 days weekly for a period of 4 weeks. The animals are put on regime lacking vitamin C. Ascorbic acid is introduced orally on 3 levels: 20 mg.kg-1 body mass (control) and with increased quantities 60 mg.kg-1 and 240 mg.kg-1 body mass. On the third day the content of ascorbic acid in some biochemical parameters of the lung is determined. Histochemical examinations of the lung tissue are made. The styrene causes decrease in the ascorbic acid content in the lung, considerable increase of the studied enzymes (lactate- and glucose-6-phosphate-dehydrogenase, alkaline and acidic phosphatase) and the concentration of the total protein in the lung. There are inflammatory, dystrophic and obturation changes. The raised intake of ascorbic acid 60 mg.kg-1 body mass doesn't effect the negative influence of styrene. The high dose (240 mg.kg-1 body mass) provokes increased activity of the examined enzymes. At inhalation with styrene this dose of ascorbic acid increases the styrene effect on the enzyme activity, especially of LDH and glucose-6-phosphate-dehydrogenase, without invigorating the pathomorphological disturbances in the lung.

Metabolism of inhaled styrene in acetone-, phenobarbital- and 3-methylcholanthrene-pretreated rats: stimulation and stereochemical effects by induction of cytochromes P450IIE1, P450IIB and P450IA

1. The effect of various cytochrome P-450 inducers, namely acetone, phenobarbital (PB) and 3-methylcholanthrene (MC), on the pharmacokinetics of styrene metabolism was studied. 2. Styrene metabolism in vivo was studied measuring phenylglyoxylic acid (PGA), the enantiomers of mandelic acid (MA), and total thioethers excreted in the urine during a 24 h period of airborne exposure to styrene at 500 cm3/m3 (2100 mg/m3). In acetone-pretreated rats, PGA and MA and thioether formation were elevated 30-50%. The R/S ratio of MA enantiomers was about two in all styrene-exposed groups except PB-pretreated rats, which showed a ratio of four. 3. Styrene metabolism in liver microsomes measured in vitro was increased by styrene 140%, acetone plus styrene by 190%, methylcholanthrene plus styrene by 180% and phenobarbital plus styrene by 250%. 4. N-Nitrosodimethylamine demethylation (NDMAD) and 7-pentoxyresorufin dealkylation (PROD) in liver microsomes were enhanced 100-150% by styrene inhalation. The metabolism of 7-ethoxyresorufin was not significantly enhanced. 5. Monoclonal antibodies to P-450 IA1, IA2, IIB1 and IIE1 were utilized to identify cytochrome P-450s by Western blot analysis. These studies showed clearly that styrene inhalation induced principally cytochrome P450IE1, whereas styrene given by gavage at a high narcotic dosage induced both P450IIE1 (NDMAD, 60%) and P450IIB (PROD, 3000%). 6. Our conclusions are that styrene metabolism in vivo in both autoinduced and induced by other foreign compounds, that cytochrome P450IIE1 induction has a major impact on styrene metabolism and that P450IIB1 induction yields an altered MA metabolite enantiomer ratio.

[Ontogenetic characteristics of the body response to chronic exposure to chemical substances]

Chronic intoxication by carbon oxide and long-term exposure to hypoxic hypoxia produced more favourable reactions in animals, exposed to these in the early terms of ontogenesis. The observed regularity was not found under chronic exposure to styrene and epichlorohydrin ++. A supposition is made on the evolutionary predetermination of this effect pertaining to unfavourable factors of hypoxic nature.

Direct determination of styrene-7,8-oxide in blood by gas chromatography with flame ionization detection

A simple capillary gas chromatographic method is described for direct determination of styrene-7,8-oxide (styrene oxide) in blood samples of 1 ml, with a detection limit of 1 ng/ml. After the addition of 1-phenylpropylene oxide as internal standard, blood samples were extracted with n-hexane, the n-hexane phases were concentrated under nitrogen, and up to 25 microliters of the resulting solution were injected on-column using a retention gap. Separation was carried out on a fused-silica capillary column coupled to a flame ionization detector. Using this method the metabolism of styrene oxide in rat blood was investigated. Concentrations of styrene oxide in the blood of rats exposed to styrene at atmospheric concentrations between 20 and 800 ppm for 3 h at steady-state conditions are reported.

Metabolism and hepatorenal toxicity due to repeated exposure to styrene in spontaneously hypertensive rats (SHR)

Groups of adult male rats (5 rats per group), either normotensive (WKY) or spontaneously hypertensive (SHR), were exposed by inhalation to 0, 821, and 3018 ppm styrene, 5 h per day for 3 consecutive days. After the exposure, the urines were collected for 24 h and the animals were then sacrificed. The various biochemical parameters of hepatorenal toxicity due to styrene as well as its urinary metabolites were measured. Hepatotoxicity due to styrene was not further increased at any exposure level due to hypertension. However, repeated exposure of SHR rats to 3018 ppm styrene showed significant increases in the urinary excretion of gamma-glutamyl transpeptidase, proteins, and volume of urine, compared to WKY treated rats, whereas no such changes were observed due to repeated exposure to 821 ppm styrene. Studies of in vivo metabolism of styrene at higher exposure level showed significant decrease in the urinary excretion of mandelic, phenylglyoxylic, and hippuric acids in SHR rats compared to WKY-treated rats, suggesting an inhibition of deactivation of styrene reactive intermediate involving the epoxide hydrase pathway due to hypertension. At the same time, a significant increase in the urinary excretion of a potential nephrotoxic metabolite of styrene (e.g., mercapturates or thioethers) was observed in SHR-treated rats when compared to WKY-treated rats. These results demonstrate that spontaneous hypertension has the potential to further increase the nephrotoxicity due to repeated exposure to styrene, and the metabolism of styrene plays an important role in modifying such toxicity in the hypertensive state.

Long-term carcinogenicity bioassays on styrene administered by inhalation, ingestion and injection and styrene oxide administered by ingestion in Sprague-Dawley rats, and para-methylstyrene administered by ingestion in Sprague-Dawley rats and Swiss mice

Styrene was administered to Sprague-Dawley rats by inhalation (300, 100, 50, 25, 10 and 0 ppm, 4 hours daily, 5 days weekly, for 52 weeks); by gavage (250, 50 and 0 mg/kg b.w. in olive oil, once daily, 4-5 days weekly, for 52 weeks), by intraperitoneal injection (50 and 0 mg in olive oil, four times at 2-month intervals), by subcutaneous injection (50 and 0 mg in olive oil, once). Styrene oxide was administered to Sprague-Dawley rats by gavage as styrene (250, 50 and 0 mg/kg b.w. in olive oil, once daily, 4-5 days weekly, for 52 weeks). The animals were kept under observation until spontaneous death. Para-methylstyrene was also administered by gavage to Sprague-Dawley rats at 500, 250, 50, 10 and 0 mg/kg b.w., and to Swiss mice at 250, 50, 10 and 0 mg/kg b.w., in olive oil, once daily, 5 days weekly, for 108 weeks and 78 weeks, respectively. The study was terminated when the survival rate reached 50% in at least one experimental group. Styrene, when given by inhalation, was found to cause an increase in total (benign and malignant) and malignant mammary tumors. Styrene oxide produced a high incidence of tumors in the forestomach (papillomas, acanthomas, and in situ and invasive squamous cell carcinomas). Para-methylstyrene was not shown to be carcinogenic.

Effects of styrene on wheel-running and ambulatory activities in mice

Effects of styrene on wheel-running and ambulatory activities were investigated in mice. Sixty male mice (ICR strain) were divided into 10 groups of six mice each, and they were exposed to styrene of about 930, 425, 60, 25 or 0 ppm (control group) for 4 hours a day, 5 days a week over 2 weeks. The wheel-running and ambulatory activity tests were conducted during 2 weeks of the styrene exposure, and 1 week before and after the exposure. The wheel-running activity decreased at the high concentrations (930 and 425 ppm), and the decreased activity did not recover to the control level after cessation of the exposure. In the ambulatory activity test, styrene exposure resulted in the decrease in the activity, though the change was not concentration-dependent. The present results suggest that the behavioral effect of styrene is clearly detectable by means of wheel-running and ambulatory activities in mice.

Synthesis of alpha-methyl-benzamido-alpha'-substituted styryl cyclohexanone thiosemicarbazones as potential antifertility agents

Cyclohexanone was condensed with N-hydroxymethyl benzamide in conc. sulphuric acid to give alpha-methyl-benzamido-cyclohexanone (I). The reaction of (I) with thiosemicarbazide in ethanol resulted in alpha-methyl-benzamido-cyclohexanone thiosemicarbazone (II). Condensation of (II) with various aromatic aldehydes in the presence of ethanol afforded alpha-methyl-benzamido-alpha'-substituted-styryl-cyclohexanone thiosemicarbazones (III) in yields ranging from 40 to 50 percent. The compounds exhibited pronounced antiimplantation activity in female albino rats.

Occurrence of styrene-7,8-oxide and styrene glycol in mouse after the administration of styrene

Styrene-7,8-oxide and its hydrated product styrene glycol were determined in mouse tissues at different times (0.5-5 h) after the intraperitoneal administration of 7-[14C]-styrene (3.8 mmol/kg). In a study of the influence of dose on the metabolite pattern of styrene, mice were killed 2 h after a dose of 1.1, 2.3, 3.4, and 5.1 mmol/kg, respectively. The mouse tissues studied (blood, liver, kidney, lung, brain, subcutaneous adipose tissue) were isolated and extracted first with hexane to remove styrene and styrene-7,8-oxide and then with ethyl acetate to remove styrene glycol. beta-Glucuronidase was used to liberate conjugated styrene glycol. A gas-liquid chromatographic method based on the use of an electron capture detector (GLC-EC) was used to quantify styrene glycol, as well as styrene-7,8-oxide, after hydrolysis. In addition all homogenates and extracts were assayed by radioactivity counting. Styrene-7,8-oxide and styrene glycol reached maximum concentrations within 2 h. The highest levels of styrene-7,8-oxide were detected in the kidneys and subcutaneous adipose tissue, while the lungs showed the lowest levels. Styrene glycol was found in the highest concentrations in the kidneys, liver, blood, and lungs. The concentration of unmetabolized styrene increased exponentially at higher doses. There seemed to be a linear increase with the dose of styrene-7,8-oxide and styrene glycol in all the tissues studied. The more polar metabolites occurred at relatively lower levels in the liver and kidneys at higher doses. In a complementary study the epoxide hydratase inhibitor trichloropropene oxide was added to the removed tissues, and the hexane extracts were analyzed for styrene-7,8-oxide both by GLC-EC and mass spectrometry (GLC-MS).

Tissue distribution of styrene, styrene glycol and more polar styrene metabolites in the mouse

A primary objective of the present investigation was to determine the tissue distribution of styrene, styrene glycol, and more polar metabolites in mice at different times (0.5-5 h) after the intraperitoneal administration of styrene (3.3 mmol/kg). Another aim was to determine the dose dependence of the metabolite pattern of styrene in the different tissues. The dose range chosen was 1.1-4.9 mmol of styrene/kg administered intraperitoneally, and the time delay 2 h after dosing. The highest initial concentrations of unchanged styrene were found in adipose tissue, pancreas, liver, and brain. Styrene glycol reached its maximum concentration within 1 h in most tissues. The levels in the kidneys, lungs, pancreas, and liver far exceeded those in subcutaneous adipose tissue. Only in the liver and kidneys was a notable amount of styrene glycol conjugated. Polar metabolites occurred to a considerable extent in the liver, kidneys, lungs, and plasma. The concentration of unmetabolized styrene seemed to increase exponentially with the dose in subcutaneous adipose tissue, liver, kidneys, lungs, and brain. No tendency towards a decreased relative occurrence of styrene glycol was observed at higher doses. However, when the dose was increased, the more polar metabolites occurred at relatively lower levels in all tissues except brain.

Bone marrow cell chromosomal aberrations and styrene biotransformation in mice given styrene on a repeated oral schedule

Styrene's capacity to induce chromosomal aberrations was studied in bone marrow cells of CD1 male mice. No mutagenic effect could be detected after either a 4-day treatment course with daily oral doses of 500 mg/kg or a 70-day course with daily oral doses of 200 mg/kg. Urinary elimination of styrene metabolites related to styrene-7,8-oxide formation (i.e. phenylethylene glycol, mandelic acid, benzoic acid, phenylglyoxylic acid and total mercapturic acids) was quantitatively evaluated in the group of mice given the 200 mg/kg dose. In parallel, kinetic studies were made on styrene and styrene-7,8-oxide blood concentrations in the same group of animals. These determinations were carried out on days 1 and 70 of treatment by spectrophotometric, gas chromatographic and mass fragmentographic procedures. Not even nanograms of styrene-7,8-oxide were found in the blood of styrene-treated mice. This suggests that the metabolite does not migrate from the cellular compartment where it is formed being immediately metabolized or irreversibly bound to cellular structures. This observation could well explain the lack of mutagenic effects observed.

[The toxicological evaluation of styrene as an industrial chemical]

Recent development in toxicological study of styrene is summarized from the viewpoint of occupational health. The topics discussed are: 1) physico-chemical properties, 2) industrial use, work place environments and exposure control, 3) metabolism and biological monitoring of exposure, 4) general toxicity with special reference to dose-effect/response relationship in humans, and 5) in vitro and in vivo mutagenicity, mammalian teratogenicity and human/subhuman carcinogenicity. With 137 references.

[Functional-morphologic features of the adrenal cortex in white rats during protracted exposure to styrene]

Experiments on rats showed that long-term styrene exposure suppresses both specific and nonspecific cell metabolic indices in different adrenocortical areas. However, the sensitivity of the different areas proved to vary under styrene exposure. This allows the suggestion that each area undergoes different degree of damage which brings about the disturbance of optimum correlations between various functions of the adrenal cortex. Administration of metapirone during the first weeks of exposure diminishes the main effect of styrene. It is concluded that one of the possible factors leading to the development of abnormalities under chronic exposure to aromatic hydrocarbons may involve the breach of the correlations between different structural components of the adrenal cortex thereby favouring the maintenance of the whole body discordance.

Distribution, elimination and retention of styrene in rats

In rats exposed to styrene for 4 hours, the rate constant of elimination and biological half life of styrene were 0.11 and about 6 hours for adipose tissue, and 0.3 to 0.4 and about 2 hours for the other tissues, respectively. The relative ratio of apparent distribution of styrene decreased in the order adipose tissue much greater than liver greater than brain greater than kidney greater than blood not equal to spleen greater than muscle. Almost the same results were obtained in the experiment by intraperitoneal injection of styrene. Repeated 4-hour exposures at about 700 ppm daily for five days caused the results similar to those in a single exposure. A trend of increase in concentration of styrene was observed in adipose tissue by 5 successive intraperitoneal injections every 6 hours at a dose of 350 mg/kg.

The effect of maternally inhaled styrene on embryonal and foetal development in mice and Chinese hamsters

Pregnant mice and Chinese hamsters were exposed to styrene 6 hrs daily during the period of major organogenesis via inhalation in concentrations 250 p.p.m., and 300, 500, 750 and 1000 p.p.m., respectively. Both in mice and in Chinese hamsters embryotoxicity was raised. Some minor skeletal malformations (rib fusions, extra ribs) were noted in mice but not in Chinese hamsters.